Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr
The Perfect Holiday Gift Gift Now

Can India Eliminate TB by 2025?

BioSpectrum Asia

|

BioSpectrum Asia March 2023

Tuberculosis (TB) is a severe public health issue in India, accounting for a quarter of the global TB burden.

Can India Eliminate TB by 2025?

While the World Health Organisation (WHO) has set a goal to end the TB epidemic by 2030, India committed to ending the disease by 2025, a mission backed by Prime Minister Narendra Modi. But the crucial question here is whether it is an achievable target?

According to the WHO, only 60 per cent of TB cases in India are notified to the national TB programme. Incidentally, most patients do not seek medical attention at all or are not diagnosed until the disease is in its advanced stages. At this juncture, technology comes in to assist in early and better TB detection. Early detection is a key strategy called out in the Global Plan to End TB.

Challenges on the road

Despite technological advancements, numerous challenges remain in the fight against TB in India. One of the biggest is the lack of access to healthcare in rural and remote locations. Many people in these areas do not have access to the same resources and technology as those living in urban areas. They may not have the necessary awareness to seek medical attention in time; even if they do, the plight of Primary Health Centres (PHCs) in rural locations abates the situation. The PHCs do not have access to diagnostic tools and suffer from a severe shortage of trained personnel to read reports and guide patients onto the correct treatment pathway. All of these factors, coupled with the rising cost of care, make diagnosing and treating TB significantly tougher.

Another challenge is the high number of drugresistant TB cases in India. This type of TB is much harder to treat and requires more expensive, specialised drugs and a longer duration of treatment. Lack of research and an inability to implement measures to cap the treatment and drug costs are aiding the spread of the epidemic. Though India has a detailed National Strategic Plan

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

"The next 5-years will see mRNA science evolve beyond infectious disease"

A new survey from Moderna Singapore reveals persistent vaccine hesitancy among older adults in Singapore, even as international travel and year-end gatherings increase the urgency of protection. The findings point to clear opportunities to strengthen public health, including empowering healthcare professionals as trusted messengers and promoting co-administration of vaccines.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

No Funding No Vax for TB?

The World Health Organization (WHO)'s latest updates on tuberculosis (TB) released on November 12 reveal significant progress in diagnosis, treatment, and political commitment, but also expose deep vulnerabilities—especially in the South-East Asia Region (SEARO)—related to funding gaps and the uncertain future of novel TB vaccines. SEARO remains the global epicentre of the TB epidemic, carrying more than 45 per cent of the world's TB incidence despite representing only a quarter of the global population.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Australia builds tailored heart pump to transform heart failure care

Despite making up half of the 64 million people living with heart failure, patients with this common form have no access to heart pump treatments and are left with only medication or palliative care.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Clinical Research Trends 2026: Hybrid DCTs Set for Surge as Innovation Outpaces Regulatory Hurdles

APAC's openness to innovation, combined with its large population and low trial density, creates strong potential for expanding decentralised clinical trials (DCTs), especially for patients with limited trial access. While regulatory diversity and operational challenges will continue to hinder fully decentralised models, the region is expected to adopt more digital technologies in clinical research. As a result, hybrid DCTs will keep gaining traction, and effective management of digitally collected data will remain a central focus for data science teams.

time to read

4 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

CSL Seqirus to localise advanced influenza vaccine manufacturing in Saudi Arabia

Australia-based CSL Seqirus and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by accessing advanced cellbased seasonal and pandemic influenza vaccines and localising manufacturing in Saudi Arabia.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

How Sponsors Could Gain Advantage by Embracing Dose Optimisation in Asia by 2026

In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm toward evidence-based dose optimisation. Sponsors might consider adopting strategies similar to the FDA's Project Optimus, which emphasises selecting doses that balance efficacy and safety rather than relying solely on toxicity thresholds. Doing so could improve patient outcomes and position companies favourably as regulatory expectations evolve.

time to read

1 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Fujifilm launches joint research with National Cancer Center in Japan

Fujifilm Corporation has signed a joint research agreement with the National Cancer Center Japan, a Tokyo-based national institution recognised for its leadership in cancer care and research.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Monash spinout RAGE Biotech secures $29 M to advance next-generation RNA therapeutics

Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.

time to read

1 min

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Submitting clinical data to the FDA and PDMA: An efficient and compliant approach

In both the US and Japan, regulators provide an extensive set of resources detailing the rules and specifications governing submissions for marketing approval of new drugs and biologics. Fortunately, despite some differences, the regulations concerning clinical data have a surprising amount in common. It is possible that with a solid understanding of the requirements and an adherence to best practices, sponsors can develop some of the same material for submission to both countries.

time to read

2 mins

BioSpectrum Asia Dec 2025

BioSpectrum Asia

BioSpectrum Asia

Regenerative medicines and microbiome health are emerging as exciting frontiers, with Australian companies and researchers pushing into new therapeutic approaches

After more than a year at the helm of AusBiotech, CEO Rebekah Cassidy reflects on her early priorities and the organisation’s ambitions as Australia accelerates its position in the global life sciences economy. In an email interaction on the sidelines of AusBiotech 2025, she highlights the country's progress in mRNA, cell and gene therapy, and radiopharmaceuticals, outlines emerging areas of momentum, and discusses how new partnerships and MoUs are strengthening collaboration across the biotech ecosystem. Rebekah also outlines how AusBiotech is preparing Australia for a more competitive and connected global life sciences economy and the strategic priorities shaping AusBiotech’s next chapter. Edited excerpts:

time to read

7 mins

BioSpectrum Asia Dec 2025

Translate

Share

-
+

Change font size

Holiday offer front
Holiday offer back